Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin) December 22, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans December 21, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia December 7, 2020 • 7:00 AM EST
Vaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus December 4, 2020 • 8:00 AM EST
Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates November 16, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit November 12, 2020 • 4:31 PM EST
Tonix Pharmaceuticals to Participate in Upcoming November Conferences November 11, 2020 • 7:00 AM EST
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit November 9, 2020 • 4:15 PM EST
Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights November 9, 2020 • 8:30 AM EST
Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics October 15, 2020 • 7:00 AM EDT
